MAPS Releases Ibogaine Investigator’s Brochure as Open-Access Resource
Event summary
- MAPS published a comprehensive Ibogaine Investigator’s Brochure (IB) as a free, open-access resource on July 7, 2026.
- The IB compiles preclinical, safety, dosing, and observational data on ibogaine, typically held as proprietary industry assets.
- Texas committed over $100 million to ibogaine clinical trials, and Colorado expanded its regulated use program to include ibogaine.
- FDA cleared the first U.S. Investigational New Drug (IND) application for noribogaine, the principal active metabolite of ibogaine.
The big picture
MAPS’ release of the Ibogaine Investigator’s Brochure as an open-access resource marks a strategic shift in psychedelic research, democratizing access to critical scientific data. This move comes amid growing state and federal investment in ibogaine, signaling a pivotal moment for the field. The brochure aims to support not just clinical drug development but also broader research and public health efforts, emphasizing sustainability and reciprocity with source communities.
What we're watching
- Regulatory Dynamics
- How state and federal regulatory shifts will affect ibogaine’s path to mainstream medical use.
- Industry Collaboration
- Whether MAPS’ open-access approach can sustain broader industry adoption of similar practices.
- Market Expansion
- The pace at which institutional investment in ibogaine accelerates following this regulatory and scientific milestone.
Related topics